Global Insights from MATTERHORN: Unifying Gastric Cancer Treatment Standards with Durvalumab and FLOT
In this MEDtalk, Dr. Janjigian presents a comprehensive analysis from the global MATTERHORN study, showcased at ASCO GI. The study investigates the efficacy of durvalumab in combination with the FLOT regimen for treating localized, non-metastatic gastric and gastroesophageal adenocarcinoma. The study’s international scale is noteworthy, incorporating a diverse cohort of patients from Asia, Europe, and both South and North America. This extensive reach underscores the study’s potential to standardize gastric cancer treatment protocols across various geographic regions, thereby harmonizing the management strategies despite regional differences in disease presentation and response to therapy.”
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.